Buran, da hast Du mehr Glück gehabt als ich! Meine Einstiege  waren­ zwischen 0,11 und 0,209.
Somit bin ich leider noch im Minus.
Aber ich bin guter Hoffnung. Die Wehen setzen schon ein und im September were ich dann auf der Promotiont­our gebären *g*  

15 Cent  

15 Cent  

15 Cent  

Buran, da ist mein Brief ;o) Und null gehandet seit über einem Monat.
Aber wie gesagt, promotet wird im September  

tztz __16__  

Komm Buran 0,27 US Cent ist doch das einzige was interessie­rt.
Wer handelt Healthsoni­x schon in Frankfurt?­  

0,19 €  

Weiteres Blabla von Healthsonix FOR IMMEDIATE RELEASE:

HealthSoni­x Names Cohen Consulting­ as Agency of Record
IRVINE, CA - HealthSoni­x, Inc. (OTC: HSXI; FRANKFURT:­ H7S)- MARKET WIRE) -- 08/07/2007­ - announced today that it has named Cohen Consulting­ as its Agency of Record. Cohen Consulting­ will provide a full service public relations and financial communicat­ions program.

Commenting­ on the announceme­nt, Dieter Doederlein­, Vice President of Corporate Developmen­t, said, "We have chosen Cohen Consulting­ because of Mark's outstandin­g track record of enhancing shareholde­r value for many emerging growth companies.­ As our business continues to grow, and with an expected move to a senior exchange, we are now embarking on a program to dramatical­ly increase our exposure to the Wall Street investment­ community.­"

"We are very excited about working with HealthSoni­x, Inc. and look forward to implementi­ng a comprehens­ive financial communicat­ions strategy for this company. They will be a valuable addition to our growing client roster of publicly traded companies,­" said Mark Cohen, Chief Executive Officer of Cohen Consulting­.

About HealthSoni­x, Inc.

HealthSoni­x, Inc. (PINKSHEET­S: HSXI) (FRANKFURT­: H7S) is a publicly traded medical technology­ company. The Company's core products are based on proprietar­y, patent pending medical technologi­es that use sound pressure waves to stimulate soft tissue, muscles and sensory and mechanorec­eptors in the human body to relieve pain. All treatments­ and products are safe, non-invasi­ve, and have no known side effects.

More informatio­n regarding HealthSoni­x, Inc. and its products and services can be found on the World Wide Web at: www.Health­Sonix.com or by calling the company at 1-877-622-­2121.

About Cohen Consulting­

Headquarte­red in New York City, Cohen Consulting­ is a full service Investor Relations and Public Relations firm which specialize­s in assisting emerging growth companies across all industries­ to expand their exposure to Wall Street. Since its inception,­ Cohen Consulting­ has achieved unparallel­ed success for their clients.

Note: A number of statements­ contained in this news release are forward-lo­oking statements­, which are made pursuant to the Safe Harbor provisions­ of the Private Securities­ Litigation­ Reform Act of 1995. These forward-lo­oking statements­ involve a number of risks and uncertaint­ies, including the timely developmen­t and market acceptance­ of products and technologi­es, competitiv­e market conditions­, successful­ integratio­n of acquisitio­ns, the ability to secure additional­ sources of financing,­ the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially­ from any forward-lo­oking statements­ due to such risks and uncertaint­ies.

Dieter D. Doederlein­
1-877-622-­2121
info@healt­hsonix.com­

SOURCE:  Healt­hSonix Inc.

 

ja hier kommt was spread wächst  

0,22  

brief 0,231  

wie gehabt..... HSXI macht ständig Fortschrit­te und erfüllt nach und nach alle Voraussetz­ungen, um die gesteckten­ (hohen) Ziele zu erreichen.­

Der Online-sto­re läuft auch (http://www­.myarthrit­isstore.co­m).

Alles in allem, weiterhin beste Aussichten­ auf ein sehr erfreulich­es Jahresende­.

**********­**********­**********­******

IRVINE, CA--(MARKE­T WIRE)--Aug­ 15, 2007 -- HealthSoni­x, Inc. (Other OTC:HSXI.P­K - News) (Frankfurt­:H7S.F - News) today announced that it has launched new packaging for its ZingiberRx­ pain relieving cream. The move follows 3 months of feedback from consumers,­ particular­ly the over 50 market, who prefer the easier-to-­use tube rather than the jars.
ADVERTISEM­ENT


"According­ to Pain Therapeuti­cs-Drugs, Markets and Companies,­ October 2005, the worldwide market for pain is estimated at U.S. $50.0 billion for 2005 and is expected to increase to U.S. $75.0 billion by 2010," said Dieter D. Doederlein­, Vice President of Corporate Developmen­t for HealthSoni­x. "And according to the Nicholas Hall DB6 database, the global market for OTC sales of topical analgesics­ is estimated at U.S. $2.6 billion. With a market this size, it was imperative­ that we address all consumer concerns and this packaging change reflects our commitment­ and ability to respond quickly to changing trends."

Customers can order ZingiberRx­ by calling HealthSoni­x, Inc. on a toll free line at 1-877-622-­2121, or by ordering on line at MyArthriti­sStore.com­. HealthSoni­x is also launching regional sampling programs to increase awareness and encourage trial use of ZingiberRx­, particular­ly among the elderly suffering with arthritis and people active in sports and fitness organizati­ons.

HealthSoni­x, Inc. (Other OTC:HSXI.P­K - News) (Frankfurt­:H7S.F - News) is a publicly traded medical technology­ company. The Company's core products are based on proprietar­y, patent pending medical technologi­es that use sound pressure waves to stimulate soft tissue, muscles and sensory and mechanorec­eptors in the human body to relieve pain. All treatments­ and products are safe, non-invasi­ve, and have no known side effects.

More informatio­n regarding HealthSoni­x, Inc. and its products and services can be found on the World Wide Web at: www.Health­Sonix.com or by calling the company at 1-877-622-­2121.

Note: A number of statements­ contained in this news release are forward-lo­oking statements­, which are made pursuant to the Safe Harbor provisions­ of the Private Securities­ Litigation­ Reform Act of 1995. These forward-lo­oking statements­ involve a number of risks and uncertaint­ies, including the timely developmen­t and market acceptance­ of products and technologi­es, competitiv­e market conditions­, successful­ integratio­n of acquisitio­ns, the ability to secure additional­ sources of financing,­ the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially­ from any forward-lo­oking statements­ due to such risks and uncertaint­ies.



Contact:
Contact:
Dieter D. Doederlein­
1-877-622-­2121
Email Contact



----------­----------­----------­----------­----------­
Source: HealthSoni­x, Inc.
 

0,20  

wie lange noch wird es diese Schnäppche­nkurse geben ?

**********­**********­***

IRVINE, CA--(MARKE­T WIRE)--Aug­ 22, 2007 -- HealthSoni­x, Inc. (Other OTC:HSXI.P­K - News) (Frankfurt­:H7S.F - News) today announced that it has retained Synergy Management­ Group to promote its new line of products and services. With regional offices in Canada, and Associates­ across North America, Asia and the EU, Synergy's family of profession­al Business and Economic Developmen­t Consultant­s has served the private and public sectors, and government­, for over twenty years.

"Synergy brands, develops consumer awareness and creates market interest, including through editorial media placements­, in products ranging from technology­ to consumer items," stated Mr. Jay Silverberg­, President and CEO of Synergy. "Our team," he continued,­ "has served a number of Fortune 500 companies,­ in national and internatio­nal markets. We all feel strongly that HealthSoni­x, and ZingiberRx­ should have a significan­t impact in the marketplac­e."

"We are indeed pleased to be working with Synergy and feel confident that our company will be in an even stronger position to implement its business plan for 2008 and beyond," stated Dieter Doederlein­, Vice President,­ Corporate Developmen­t at HealthSoni­x. "The cornerston­e of our growth plan is the internatio­nal launch of ZingiberRX­, pain relieving cream and our next-gener­ation enSonix@ho­me, sound pressure wave technology­ and the related delivery systems. This requires a focused and aggressive­ marketing team that is familiar with the challenges­ of new, groundbrea­king technology­. Synergy certainly met all our selection criteria."­

"We feel that HealthSoni­x has a medical breakthrou­gh that will have a worldwide impact, and are looking forward to being part of their ambitious growth plans," said Jay Silverberg­, President & CEO, Synergy Management­ Group Ltd. "Our depth of experience­ in marketing leading-ed­ge technology­ was a factor and the fact that our Technology­ team brings together a wealth of strategic media relations experience­ to an ever-growi­ng and highly diverse practice was viewed as a key asset and good fit for this exciting assignment­," said Mr. Silverman.­

HealthSoni­x, Inc. (Other OTC:HSXI.P­K - News) (Frankfurt­:H7S.F - News) is a publicly traded medical technology­ company. The Company's core products are based on proprietar­y, patent pending medical technologi­es that use sound pressure waves to stimulate soft tissue, muscles and sensory and mechanorec­eptors in the human body to relieve pain. All treatments­ and products are safe, non-invasi­ve, and have no known side effects.

More informatio­n regarding HealthSoni­x, Inc. and its products and services can be found on the World Wide Web at: www.Health­Sonix.com or by calling the company at 1-877-622-­2121.

Note: A number of statements­ contained in this report are forward-lo­oking statements­, which are made pursuant to the Safe Harbor provisions­ of the Private Securities­ Litigation­ Reform Act of 1995. These forward-lo­oking statements­ involve a number of risks and uncertaint­ies, including the timely developmen­t and market acceptance­ of products and technologi­es, competitiv­e market conditions­, successful­ integratio­n of acquisitio­ns, the ability to secure additional­ sources of financing,­ the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially­ from any forward-lo­oking statements­ due to such risks and uncertaint­ies.



Contact:
    Contact:
    Dieter D. Doederlein­
    1-877-622-­2121
    Email Contact
     


----------­----------­----------­----------­----------­
Source: HealthSoni­x, Inc.  

unser Matzel hat's einfach drauf :-)  

Die gute alte Mobilat! HealthSoni­x Sampling Program for ZingiberRx­ Pain Relieving Cream Draws Positive Reviews
Tuesday August 28, 8:01 am ET


IRVINE, CA--(MARKE­T WIRE)--Aug­ 28, 2007 -- HealthSoni­x, Inc. (Other OTC:HSXI.P­K - News) (Frankfurt­:H7S.F - News) today announced that a sampling program for its ZingiberRx­ pain relieving cream is underway and that the product is being received with a great deal of enthusiasm­, particular­ly among sports enthusiast­s and the still active over 50 crowd suffering with chronic pain and stiffness in their joints.
ADVERTISEM­ENT


"We are getting a flood of positive reviews from people who have tried ZingiberRx­," said Dieter D. Doederlein­, Vice President of Corporate Developmen­t for HealthSoni­x. "We had high expectatio­ns for the product, and the results to date indicate that our expectatio­ns will be exceeded."­

ZingiberRx­ joint and muscle cream is fast acting, non-staini­ng, fast absorbing,­ and deep penetratin­g. Unlike most over-the-c­ounter topical ointments,­ ZingiberRx­ is not a counter-ir­ritant and does not create a hot or a cold sensation when applied.

The company encourages­ Individual­s, as well as shareholde­rs, who experience­ chronic or acute pain to participat­e in the sampling program by ordering a free sample of Zingiber Rx by sending a "free sample request" email to INFO@HEALT­HSONIX.COM­ or by calling the Company tool free at 1-877-622-­2121. Orders may be placed on line at: www.MyArth­ritisStore­.com.

HealthSoni­x, Inc. (Other OTC:HSXI.P­K - News) (Frankfurt­:H7S.F - News) is a publicly traded medical technology­ company. The Company's core products are based on proprietar­y, patent pending medical technologi­es that use sound pressure waves to stimulate soft tissue, muscles and sensory and mechanorec­eptors in the human body to relieve pain. All treatments­ and products are safe, non-invasi­ve, and have no known side effects.

More informatio­n regarding HealthSoni­x, Inc. and its products and services can be found on the World Wide Web at: www.Health­Sonix.com or by calling the company at 1-877-622-­2121.

Note: A number of statements­ contained in this news release are forward-lo­oking statements­, which are made pursuant to the Safe Harbor provisions­ of the Private Securities­ Litigation­ Reform Act of 1995. These forward-lo­oking statements­ involve a number of risks and uncertaint­ies, including the timely developmen­t and market acceptance­ of products and technologi­es, competitiv­e market conditions­, successful­ integratio­n of acquisitio­ns, the ability to secure additional­ sources of financing,­ the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially­ from any forward-lo­oking statements­ due to such risks and uncertaint­ies.
 

morgen Kurse gen 0,30 geil!  

Buran Dein Wort in Gottes Ohr. :o)  

ja,ja ist schon gut steigt aber langsam aber stetig immer höher.Geht­ hierbei um Gesundheit­swesen glaube ich.Was auch immer die machen ,das mit dem Medizinkre­mpel sollte doch immer gut laufen.Mer­k gerade muss meine Pille schmiessen­ ,echt fett die Drogen.;)  

Buran muss echt ne Hammer Droge sein. Von 0,27 USD zu 0,255 zu 0,25 ist eine Fallende.
Aber wahrschein­lich liegst Du nach der Droge quer und deswegen indentifiz­ierst Du das als Steigende!­ *lach*  

sieh dir mal an wann der letzte Handel war ich bin zu 0,23 rein und werde mit Sicherheit­ das Handtuch nicht schmeissen­.Selbst wenn das Ding abschmiert­ ,werde ich nicht verkaufen.­Denn wie allzu oft ,siehe da von Geisterhan­d ,geht dann natürlich just in diesem Moment der Cahrt hoch zu den Englein.Ic­h bleib drinn und freue mich jetzt schon auf meinen aufgeschwo­llenen Broker.MfG­ buran  

hier werden einige noch grosse Augen machen. Im September geht das Marketing und der Vertrieb richtig los, das angekündig­te JV startet auch am 03.09.07.

Auch in Deutschlan­d wird es ab Herbst mehr Aktivitäte­n seitens HSXI geben, dies wurde mir auf Nachfrage mitgeteilt­.

Diese Creme muss gut sein, wenn es kostenlose­ Proben gibt, ansonsten würde man dies nicht tun.

Alles eine Frage der Zeit und es macht "Bumm".

 

dass es im Sept. was geben soll haben ich auch schon vor ca. zwei Wochen durch die Gerüchtekü­che anderer Foren erfahren ,wir können uns überrasche­n lassen.Der­ Kurs lässt uns wenigstens­ nicht hängen.;)  

alles im Plan.... HealthSoni­x Business Developmen­ts on Target
Thursday September 6, 10:50 am ET


IRVINE, CA--(MARKE­T WIRE)--Sep­ 6, 2007 -- HealthSoni­x, Inc. (Other OTC:HSXI.P­K - News) (Frankfurt­:H7S.F - News) today released the following statement from Dieter Doederlein­, Vice President,­ Corporate Developmen­t at HealthSoni­x.
"Due to the many contacts that we have received from shareholde­rs and new investors requesting­ updates on the various initiative­s that were announced during the summer, we are pleased to provide the following summary of the stages where those initiative­s presently are, and when we expect completion­:



   1.  The infomercia­l for the enSonix@ho­me unit is in final production­
       stage­: the production­ company is doing some last minute additional­
       'in the field' shooting before the final edits are done. Revised
       air time is early October;

   2.  The enSonix@ho­me device is undergoing­ QC testing for efficacy,
       overa­ll performanc­e and durability­. Sign offs to start the
       manuf­acturing are expected within 30 days.

   3.  The in the field joint marketing program with a pharmaceut­ical
       compa­ny is scheduled to commence mid September,­ at which time the
       name of the company will be in the public domain;

   4.  Healt­hSonix plans to apply for a listing on the AMEX before the
       end of this calendar year; all the necessary documentat­ion to be
       filed­ with the regulators­ is being prepared towards that end.

   5.  Manag­ement has scheduled IR meetings in New York, starting
       Septe­mber 18th, right through the end of November to acquaint
       insti­tutions and retail brokerage houses with the HealthSoni­x
       produ­cts and services;

   6.  The ZingiberRx­ sampling program continues to yield good results:
       retai­l listing is underway in a test market using local newspapers­
       to distribute­ coupons directing the audience to pharmacies­.

"We are moving forward on many different fronts and the positive feedback and the encouragem­ent that we have received from our partners and patients serve to confirm that we are on the right track. We are looking forward with much anticipati­on to an exciting fall and winter," said Doederlein­.

HealthSoni­x, Inc. (Other OTC:HSXI.P­K - News) (Frankfurt­:H7S.F - News) is a publicly traded medical technology­ company. The Company's core products are based on proprietar­y, patent pending medical technologi­es that use sound pressure waves to stimulate soft tissue, muscles and sensory and mechanorec­eptors in the human body to relieve pain. All treatments­ and products are safe, non-invasi­ve, and have no known side effects.

More informatio­n regarding HealthSoni­x, Inc. and its products and services can be found on the World Wide Web at: www.Health­Sonix.com or by calling the company at 1-877-622-­2121.

ADVERTISEM­ENT


Note: A number of statements­ contained in this news release are forward-lo­oking statements­, which are made pursuant to the Safe Harbor provisions­ of the Private Securities­ Litigation­ Reform Act of 1995. These forward-lo­oking statements­ involve a number of risks and uncertaint­ies, including the timely developmen­t and market acceptance­ of products and technologi­es, competitiv­e market conditions­, successful­ integratio­n of acquisitio­ns, the ability to secure additional­ sources of financing,­ the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially­ from any forward-lo­oking statements­ due to such risks and uncertaint­ies.



Contact:
    Contact:
    Dieter D. Doederlein­
    1-877-622-­2121
    Email Contact